Vor Bio Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Company Update
23 mars 2023 16h01 HE
|
Vor Biopharma
Initial clinical data supports founding vision that engineered hematopoietic stem cells can enable treatment options after AML transplantAdditional trem-cel data expected by year-end 2023; VCAR33ALLO...
Vor Bio to Participate in Upcoming Investor Conferences
21 févr. 2023 08h00 HE
|
Vor Biopharma
CAMBRIDGE, Mass., Feb. 21, 2023 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage cell and genome engineering company, today announced that it will participate in the following upcoming...
First AML Patient Transplanted with Vor Bio’s Trem-cel Demonstrated Durable Engraftment through Multiple Mylotarg™ Cycles at Initial Dose Level
16 févr. 2023 12h00 HE
|
Vor Biopharma
Trem-cel exhibited robust engraftment five months post-transplant through three cycles of MylotargMylotarg treatment enriched CD33-negative donor hematopoiesisSecond patient successfully received...
Vor Bio to Present Clinical Data from First Patient Treated with Trem-cel at 2023 Tandem Meetings
19 janv. 2023 08h00 HE
|
Vor Biopharma
CAMBRIDGE, Mass., Jan. 19, 2023 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage cell and genome engineering company, today announced that clinical data from the first patient treated in...
Vor Bio to Present at B. Riley Securities’ 3rd Annual Oncology Conference
12 janv. 2023 08h00 HE
|
Vor Biopharma
CAMBRIDGE, Mass., Jan. 12, 2023 (GLOBE NEWSWIRE) -- Vor Biopharma (Nasdaq: VOR), a clinical-stage cell and genome engineering company, today announced that it will participate virtually in B. Riley...
Vor Bio Prices Underwritten Offering of Common Stock and Concurrent Private Placement for Aggregate Proceeds of $115.8 Million
07 déc. 2022 07h45 HE
|
Vor Biopharma
CAMBRIDGE, Mass., Dec. 07, 2022 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage cell and genome engineering company, today announced the pricing of an underwritten offering and a private...
First AML Patient Successfully Transplanted with Vor Bio’s Investigational Trem-cel (VOR33) and Tolerated Mylotarg™
07 déc. 2022 07h30 HE
|
Vor Biopharma
Trem-cel (formerly VOR33) successfully manufactured and engrafted normallyBlood counts successfully maintained following post-transplant treatment with MylotargConference call scheduled for today,...
Vor Bio to Participate in Upcoming Investor Conferences
22 nov. 2022 08h00 HE
|
Vor Biopharma
CAMBRIDGE, Mass., Nov. 22, 2022 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage cell and genome engineering company, today announced that it will participate in the following upcoming...
Vor Bio Reports Third Quarter 2022 Financial Results and Provides Company Update
10 nov. 2022 16h15 HE
|
Vor Biopharma
Initial clinical data for VOR33 on track for Q4 2022Eyal C. Attar, M.D. appointed as Chief Medical OfficerInitiated in-house clinical manufacturing at Cambridge, MA headquarters CAMBRIDGE, Mass.,...
Vor Bio to Participate in Upcoming Investor Conferences
01 nov. 2022 08h00 HE
|
Vor Biopharma
CAMBRIDGE, Mass., Nov. 01, 2022 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage cell and genome engineering company, today announced that it will participate in the following upcoming...